Beam Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2021 Annual Meeting of Stockholders held by Beam Therapeutics Inc. on June 9, 2021. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, MA.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Directors): Two Class I director nominees were elected to serve until the 2024 annual meeting.
- Kristina Burow: 31,570,398 votes For; 6,874,549 votes Against; 8,883 Abstentions; 7,170,395 Broker Non-Votes.
- Graham Cooper: 34,139,249 votes For; 4,304,023 votes Against; 10,558 Abstentions; 7,170,395 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
- Votes: 45,478,127 For; 35,783 Against; 110,315 Abstentions; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that Kristina Burow and Graham Cooper have officially joined the Board of Directors.
- Verification of the significant number of broker non-votes (7,170,395) recorded for the director elections.
- Confirmation that Deloitte & Touche LLP is the appointed auditor for the 2021 fiscal year.